H.C. Wainwright raised the firm’s price target on Celldex to $80 from $73 and keeps a Buy rating on the shares after the company announced the highly anticipated top-line, randomized Phase 2 CSU with barzolvolimab, meeting the primary endpoint. Additionally, the company had announced strong Phase 1b data using bazro in prurigo nodularais patients from the World Congress on Itch, the firm adds. Detailed data are expected at a medical conference in Q1 2024. However, H.C. Wainwright believes the top-line data are “quite impressive” following the October 18 database lock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLDX:
- Celldex’s barzolvolimab meets primary endpoint in Phase 2 urticaria study
- Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
- Celldex files automatic mixed securities shelf
- Celldex reports Q3 EPS (81c), consensus (68c)
